Identification of Proteomic Subtypes with Differential Responses to Immune Checkpoint Inhibition in Cutaneous Melanoma

PURPOSE: Predictive biomarkers for combined PD-1/CTLA-4 blockade in metastatic melanoma remain limited. We analyzed pretreatment proteogenomic data to define response and resistance biology. EXPERIMENTAL DESIGN: We profiled 208 pretreatment FFPE specimens from patients with metastatic cutaneous melanoma treated across 12 institutions, including 164 receiving dual PD-1+CTLA-4 blockade (Discovery, n=97; Validation 1, n=67) and 44 receiving PD-1 monotherapy. Tumors underwent TMT-based proteomics, RNA sequencing, and targeted/low-pass whole-genome sequencing. Pathway clustering, survival modeling, deconvolution, and machine-learning classification defined and validated subtype signatures. RESULTS: Proteomic pathway clustering identified three reproducible ICI subtypes: immune-enriched ICI-sensitive, ribosome-high, and EMT-like/stromal-enriched. Subtypes stratified progression-free survival after dual ICI in the Discovery (P=0.01) and Validation 1 cohorts (P=0.02). The ICI-sensitive subtype had the highest responder fraction (74% and 73%), compared with ribosome-high (67% and 60%) and EMT-like tumors (44% and 43%) in the Discovery and Validation 1 cohorts, respectively. Subtype-outcome associations were consistent with previous immunotherapy datasets, with pooled hazard ratios ≈0.5-0.8 for immune-enriched tumors. Subtypes plus clinical variables predicted 3-year progression/death better than clinical variables alone in Validation 1 (AUC 0.80 vs 0.64). A 127-protein classifier recapitulated subtype membership in Validation 1 (AUC 0.89-0.97) and predicted 3-year progression/death with AUC 0.79. Subtypes reflected distinct immune, translational, and stromal/ECM programs and nominated POLR3A-associated biology as a candidate resistance axis. CONCLUSIONS: Proteomic pathway states define reproducible, biologically interpretable melanoma subtypes associated with differential benefit from dual PD-1/CTLA-4 blockade. A clinically tractable 127-protein classifier provides a foundation for prospective biomarker-driven combination immunotherapy trials.

Authors

Institutions

Publication Details

Journal
Clinical Cancer Research
Published
2026-11-17
DOI
https://doi.org/10.1158/1078-0432.ccr-26-2295
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Identification of Proteomic Subtypes with Differential Responses to Immune Checkpoint Inhibition in Cutaneous Melanoma

Charlotte Eielson Ariyan, Mario Sznol, John M. Kirkwood, Ryan Joseph Sullivan et al.
2 links
Clinical Cancer Research
Cancer Immunotherapy and Biomarkers
article

Identification of Proteomic Subtypes with Differential Responses to Immune Checkpoint Inhibition in Cutaneous Melanoma

Charlotte Eielson Ariyan, Mario Sznol, John M. Kirkwood, Ryan Joseph Sullivan, Genevieve Marie Boland, Tara C. Mitchell, Rose C. Pletcher, Ata S. Moshiri, Amanda G. Paulovich, Douglas Buckner Johnson, Diwakar Davar, Jacob J. Kennedy, Richard G. Ivey, Dirk Schadendorf, Giorgos Constantine Karakousis, Azra Krek, Mehdi Mesri, Paul W. Harms, Jianhui Gong, Shrabanti Chowdhury, Anna Malgorzata Czarnecka, Alexander J. Lazar, Marcin P. Cieslik, Jedd D. Wolchok, Anna Szumera‐Ciećkiewicz, Yan Chak Li, Ruth Halaban, Anne Zaremba, Georgina Venetia Long, Jeffrey R. Whiteaker, Piotr Lukasz Rutkowski, Marcus Bosenberg, Kourosh Abdollahi, Francesca Petralia, Iman Osman, Zachary T. Herbert, Jeffrey E. Gershenwald, Richard A. Scolyer, Victor Gerardo Prieto, Travis D. Lorentzen, Antonella Bacchiocchi, Tao Liu, Pei Wang, Weiping Ma, Yi Hsiao, Kelly L. Harms, Anna Xing, Nicole Tignor
article en

Abstract

PURPOSE: Predictive biomarkers for combined PD-1/CTLA-4 blockade in metastatic melanoma remain limited. We analyzed pretreatment proteogenomic data to define response and resistance biology. EXPERIMENTAL DESIGN: We profiled 208 pretreatment FFPE specimens from patients with metastatic cutaneous melanoma treated across 12 institutions, including 164 receiving dual PD-1+CTLA-4 blockade (Discovery, n=97; Validation 1, n=67) and 44 receiving PD-1 monotherapy. Tumors underwent TMT-based proteomics, RNA sequencing, and targeted/low-pass whole-genome sequencing. Pathway clustering, survival modeling, deconvolution, and machine-learning classification defined and validated subtype signatures. RESULTS: Proteomic pathway clustering identified three reproducible ICI subtypes: immune-enriched ICI-sensitive, ribosome-high, and EMT-like/stromal-enriched. Subtypes stratified progression-free survival after dual ICI in the Discovery (P=0.01) and Validation 1 cohorts (P=0.02). The ICI-sensitive subtype had the highest responder fraction (74% and 73%), compared with ribosome-high (67% and 60%) and EMT-like tumors (44% and 43%) in the Discovery and Validation 1 cohorts, respectively. Subtype-outcome associations were consistent with previous immunotherapy datasets, with pooled hazard ratios ≈0.5-0.8 for immune-enriched tumors. Subtypes plus clinical variables predicted 3-year progression/death better than clinical variables alone in Validation 1 (AUC 0.80 vs 0.64). A 127-protein classifier recapitulated subtype membership in Validation 1 (AUC 0.89-0.97) and predicted 3-year progression/death with AUC 0.79. Subtypes reflected distinct immune, translational, and stromal/ECM programs and nominated POLR3A-associated biology as a candidate resistance axis. CONCLUSIONS: Proteomic pathway states define reproducible, biologically interpretable melanoma subtypes associated with differential benefit from dual PD-1/CTLA-4 blockade. A clinically tractable 127-protein classifier provides a foundation for prospective biomarker-driven combination immunotherapy trials.

Clinical Cancer Research
Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa (ZA), Memorial Sloan Kettering Cancer Center (US), The University of Texas MD Anderson Cancer Center (US), Pacific Northwest National Laboratory (US), Cornell University (US), University of Michigan (US), Yale University (US), California University of Pennsylvania (US), Massachusetts General Hospital (US), Fred Hutch Cancer Center (US), University of Michigan–Flint (US), Michigan Medicine (US), Dana-Farber Cancer Institute (US), Yale New Haven Health System (US), Melanoma Institute Australia (AU), Essen University Hospital (DE), National Institute of Oncology (HU), National Cancer Institute (MY), University of Pittsburgh Medical Center (US), National Cancer Institute (US), Center for Cancer Research (US), The Maria Sklodowska-Curie National Research Institute of Oncology (PL), Weill Cornell Medicine (US), New York University (US), University of Pennsylvania (US), Vanderbilt University Medical Center (US), Philadelphia University (US), Icahn School of Medicine at Mount Sinai (US)
Bristol-Myers Squibb, Melanoma Research Alliance, Fred Hutchinson Cancer Research Center, University of Washington, Tizona Therapeutics, National Institutes of Health, University of Texas MD Anderson Cancer Center, National Health and Medical Research Council, National Cancer Institute, Office of Research Infrastructure Programs, National Institutes of Health
Good health and well-being
Cancer Immunotherapy and Biomarkers
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon